Role of CT in differentiation between subtypes of lung cancer; is it possible?

Gharraf, Heba Said; Mehana, El-Sayed E.; ElNagar, Mostafa Ali

doi:10.1186/s43168-020-00027-w

Cited by 17 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…small cell and Non-small Cell Lung Cancer (NSCLC). Currently, there are three treatment options for NSCLC-chemotherapy, surgical removal, and radiation therapy, but still, there is a low long-term survival rate [39]. According to recent advancements in cancer research, harnessing the body's immune system is potential in the treatment of NSCLC.…”

Section: Major Clinical Trials Failurementioning

confidence: 99%

See 1 more Smart Citation

Major Causes Associated with Clinical Trials Failure and Selective Strategies to Reduce these Consequences: A Review

Aravind¹,

Nain²,

Kumari³

et al. 2021

Arch. Pharm. Pract

View full text Add to dashboard Cite

New drug development is a highly regulated and complex process that involves the pharmaceutical industry, academic institutions, and government agencies' collaborative work. In pre-clinical testing, statistics indicate that out of 5000 compounds only five enter and evaluated in human clinical trials, moreover, only one drug is approved for human use. The whole process of drug development takes around $2-2.5 billion and a time of 12-15 years to complete. Around 50% of investigational compounds fail during the development phase of clinical trials. Despite numerous scientific and technological advancements in research and development, many clinical trials fail to develop new, safe, and effective drugs. Approximately, 70% of clinical trials fail in phase 2; whereas, the failure rate of confirmatory trials (phase 3) is around 50%. Tufts center for the study of drug development evaluated the three most common factors behind clinical trial failure-safety, efficacy, and deficient funds. Success-failure of a trial is also associated with other factors like a new molecule, molecular size, and therapeutic efficacy. As drug development involves numerous lives and billions of investments, one failed trial affects the subject's quality of life by physical/social consequences and huge losses to pharmaceutical companies. To reduce the failure rate, many biopharmaceutical companies have opted or established their own more disciplined protocol, portfolio, and progress review frameworks. These strategies reduce the chances of errors during drug development and help in clinical trials' success rate.

show abstract

Section: Major Clinical Trials Failurementioning

confidence: 99%

“…small cell and Nonsmall Cell Lung Cancer (NSCLC). Currently, there are three treatment options for NSCLC-chemotherapy, surgical removal, and radiation therapy, but still, there is a low long term survival rate [39]. Growth factor-IGF-1R contributes to the development and spreading of NSCLC, amongst other cancers [54,55].…”

Section: Major Clinical Trials Failurementioning

confidence: 99%

Major Causes Associated with Clinical Trials Failure and Selective Strategies to Reduce these Consequences: A Review

Aravind¹,

Nain²,

Kumari³

et al. 2021

Arch. Pharm. Pract

View full text Add to dashboard Cite

show abstract

“…According to the American Cancer Society, cancer was the second-leading cause of death and lung cancer caused the highest cancer deaths in the United States of America in 2017 [1] . Moreover, it is also a major cause of cancer death globally [2] , [3] , [4] .…”

Section: Introductionmentioning

confidence: 99%

Multiple intracranial metastasis from lung adenocarcinoma in a pregnant young woman: A case report

Munir

Kusumawardani

Agustina

2023

Radiology Case Reports

View full text Add to dashboard Cite

“…Figure 1 illustrates the manifestations of the three NSCLC subtypes on CT scans. The characteristics of these subtypes on CT scans [10] can be summarized as follows:…”

Section: Introductionmentioning

confidence: 99%

DETECT-LC: A 3D Deep Learning and Textural Radiomics Computational Model for Lung Cancer Staging and Tumor Phenotyping Based on Computed Tomography Volumes

2022

View full text Add to dashboard Cite

Lung Cancer is one of the primary causes of cancer-related deaths worldwide. Timely diagnosis and precise staging are pivotal for treatment planning, and thus can lead to increased survival rates. The application of advanced machine learning techniques helps in effective diagnosis and staging. In this study, a multistage neurobased computational model is proposed, DETECT-LC learning. DETECT-LC handles the challenge of choosing discriminative CT slices for constructing 3D volumes, using Haralick, histogram-based radiomics, and unsupervised clustering. ALT-CNN-DENSE Net architecture is introduced as part of DETECT-LC for voxel-based classification. DETECT-LC offers an automatic threshold-based segmentation approach instead of the manual procedure, to help mitigate this burden for radiologists and clinicians. Also, DETECT-LC presents a slice selection approach and a newly proposed relatively light weight 3D CNN architecture to improve existing studies performance. The proposed pipeline is employed for tumor phenotyping and staging. DETECT-LC performance is assessed through a range of experiments, in which DETECT-LC attains outstanding performance surpassing its counterparts in terms of accuracy, sensitivity, F1-score and Area under Curve (AuC). For histopathology classification, DETECT-LC average performance achieved an improvement of 20% in overall accuracy, 0.19 in sensitivity, 0.16 in F1-Score and 0.16 in AuC over the state of the art. A similar enhancement is reached for staging, where higher overall accuracy, sensitivity and F1-score are attained with differences of 8%, 0.08 and 0.14.

show abstract

Role of CT in differentiation between subtypes of lung cancer; is it possible?

Cited by 17 publications

References 22 publications

Major Causes Associated with Clinical Trials Failure and Selective Strategies to Reduce these Consequences: A Review

Major Causes Associated with Clinical Trials Failure and Selective Strategies to Reduce these Consequences: A Review

Multiple intracranial metastasis from lung adenocarcinoma in a pregnant young woman: A case report

DETECT-LC: A 3D Deep Learning and Textural Radiomics Computational Model for Lung Cancer Staging and Tumor Phenotyping Based on Computed Tomography Volumes

Contact Info

Product

Resources

About